PUBLICATIONS

Cardiologs Selected As Finalist for 2019 Medtech Insight Awards

15.07.2020

Cloud-based AI Solution for EKG Analysis Recognized in “Best Technological Innovation: Digital” Category

PARIS and BOSTON, Aug. 29, 2019 /PRNewswire/ — Cardiologs, a global leader in artificial intelligence (AI) cardiology diagnostics, announced today that its cloud-based AI platform that provides rapid, medical-grade electrocardiogram (EKG) analysis has been selected as a finalist for the 2019 Medtech Insight Awards. The company’s state-of-the-art FDA-cleared and CE Marked software is being recognized in the category for ‘Best Technological Innovation: Digital’.

“Our company’s growing list of honors speaks to the progress we’ve made using AI and other innovative technologies to revolutionize cardiac care,” said Yann Fleureau, co-founder and CEO of Cardiologs. “The volume of data being generated today by traditional cardiology diagnostic tools – as well as emerging wearable devices, such as the Apple Watch – is unprecedented. Our platform makes it possible to process and analyze that data at incredible speeds and with high clinical accuracy, enabling doctors to diagnose patients faster and more efficiently than ever before. We are honored to be included on the shortlist of finalists being recognized for driving positive change across the Medtech industry.”

Cardiologs developed an AI-powered cardiac diagnostic platform capable of analyzing ambulatory EKG recordings and generating patient-specific reports in a matter of minutes. Clinicians across four continents are already benefiting from the clinical accuracy and efficiency afforded by the Cardiologs platform. The solution also enables some patients to receive medical care they otherwise wouldn’t because it provides greater access to expert diagnosis in remote areas of the world. Well established in the United States, the company is now positioning itself for growth into new European countries and additional market segments in 2020.

“The Medtech Insight Awards not only recognize the achievements of innovative people, partnerships and organizations, but they are also an excellent opportunity to highlight the transformative work being done in the medical technology sector overall,” said Christopher Delporte, editor-in-chief of Medtech Insight. “Given the pace of product development, regulation and business in this industry, the awards finalists have all demonstrated their unique ability to navigate marketplace challenges and seize technological opportunity to improve patient care.”

The 2019 Medtech Insight Award winners will be announced at a gala dinner and ceremony on September 23, 2019 at the State Room in Boston during the 2019 Medtech Conference. For Cardiologs, the award adds to a growing list of accolades the company has received over the past year. Last December, the company’s medical device earned Frost & Sullivan’s 2018 New Product Innovation Award for the Global ECG Analysis Software Industry. In addition, CEO and co-founder Yann Fleureau was recently named to the European list of Forbes’ 30 Under 30, MIT Technology Review’s Innovators Under 35 in Europe, and BNP Paribas European Innovator of the Year.

A full shortlist of the 2019 Medtech Insight Award finalists can be found here.

About Cardiologs
Cardiologs is a medical technology company committed to transforming cardiac diagnostics using medical-grade artificial intelligence and cloud technology. Developed in partnership with leading physicians, the Cardiologs ECG Analysis Solution empowers clinicians worldwide to deliver expert cardiac care faster and more efficiently. CE-Marked and FDA cleared for detection of 14 cardiac arrhythmias, the Cardiologs ECG Analysis Solution is built on a growing database of more than 1.4 million ECG recordings and is supported by a number of clinical publications.

Media Contact:

Andrea LePain

andrea@emediajunction.com

617-275-8112

Cardiologs Earns Frost & Sullivan’s New Product Innovation Award

15.07.2020

Cloud-based AI Technology Recognized for Providing Faster, More Accurate EKG Analysis

PARIS and BOSTON, Dec. 9, 2019 /PRNewswire/ — Cardiologs, a global leader in artificial intelligence (AI) cardiology diagnostics, announced today it has earned global industry analysts Frost & Sullivan’s New Product Innovation Award. The pioneering cloud-based AI solution was recognized for its ability to analyze ambulatory EKG recordings faster and more reliably than traditional software, enabling clinicians to provide accurate, timely, and cost-effective arrhythmia diagnosis.

Frost & Sullivan noted in the report that, “Cardiologs has helped raise the standard of cardiac care by developing EKG analysis services that are more accurate than the solutions existing before. The cardiologist will have a reliable tool at hand which can improve the quality of diagnosis, identify patterns that may be hard to identify otherwise and positively influence medical treatment.”

“Cardiologs has pioneered the implementation of deep learning to increase EKG data analysis throughput and predictive capability, two key aspects that can reduce costs associated with providing quality healthcare. Increased throughput also means reduced patient waiting time, which is a major factor affecting utilization of healthcare,” said Megha Joshi, Research Analyst, Transformational Health, Frost & Sullivan.

Cardiologs launched in North America in 2018 where it has achieved rapid adoption of its solution in the U.S. market and continues to onboard new customers onto its service. Tens of thousands of patients have been diagnosed using the Cardiologs analysis solution, and that number is projected to increase dramatically as the company continues its expansion into additional European countries and market segments in 2020.

“Cardiovascular disease remains a leading cause of death worldwide,” said Yann Fleureau, co-founder and CEO of Cardiologs. “Our vision is to create a technology that can help democratize access to expert level healthcare, and eliminate the growing socioeconomic medical divide around the globe. As our innovative technology is more broadly adopted, Cardiologs can help improve clinical outcomes and decrease costs for treatment of cardiovascular disease on a global scale.”

Among the benefits of using Cardiologs’ technology cited in Frost & Sullivan’s report:

Increased throughput of EKG data analysis
Improved efficiency of cardiology departments
Increased number of patients that are screened for arrhythmias
Quicker diagnosis in cases of atrial fibrillation and other life-threatening arrhythmias
A full copy of the Frost & Sullivan award report can be found here.

About Cardiologs
Cardiologs is a medical technology company committed to transforming cardiac diagnostics using medical-grade artificial intelligence and cloud technology. Developed in partnership with leading physicians, the Cardiologs ECG Analysis Solution empowers clinicians worldwide to deliver expert cardiac care faster and more efficiently. CE-Marked and FDA cleared for detection of 14 cardiac arrhythmias, the Cardiologs ECG Analysis Solution is built on a proprietary database of more than 1.5 million ECG recordings and is supported by a growing number of clinical publications.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community.

Media Contact:

Andrea LePain
eMedia Junction
andrea@emediajunction.com
617-275-8112

Cardiologs Announces Clinical Study to Monitor Cardiac Safety of COVID-19 Patients Via Smartwatches

15.07.2020

Trial will evaluate use of Cardiologs’ AI platform for QT interval analysis of ECG data from smartwatches in patients receiving hydroxychloroquine treatment

BOSTON, April 22, 2020 /PRNewswire/ — Cardiologs, a global leader in artificial intelligence (AI) for cardiac diagnostics, today announced the launch of a clinical study using the company’s ground-breaking AI-based solution to remotely monitor the cardiac safety of COVID-19 patients during hydroxychloroquine treatment via analysis of electrocardiogram (ECG) data gathered from smartwatches. Hydroxychloroquine therapy is associated with the risk of QT prolongation, a specific sign found on ECGs, which can lead to severe cardiac arrhythmias.

The trial will study patients with COVID-19 at the University Hospital of Marseille in France who are being treated with hydroxychloroquine and azithromycin, a drug combination currently being evaluated as a therapy for the coronavirus (SARS-CoV-2). These drugs can cause QT prolongation as a side effect, especially when used together, raising concerns about the risk of arrhythmic death.

“A significant QT prolongation can lead to ventricular arrhythmia and potentially deadly consequences,” explained Laurent Fiorina, a cardiologist at the Institut Cardiovasculaire Paris Sud (ICPS) and a medical expert at Cardiologs who initiated the project. “It is thus important to closely monitor the QT interval during this treatment.”

ECG assessment to monitor the QT interval is the current standard of care to ensure cardiac safety in clinical settings. With COVID-19, monitoring is especially challenging to implement because of the risk of contamination. It is also highly unlikely that it could be applied as a standard to a large population within a short period of time because of the strain on hospital resources.

“The objective of our study is to evaluate a new method for QT measurement using Cardiologs’ AI-based solution and ECG data collected via smartwatches,” added Professor Jean-Claude Deharo, head of the cardiac arrhythmia department at the University Hospital of Marseille and the principal investigator of the study. “Smartwatches are already used in the clinical setting but do not have validated QT analysis available. Combining these technologies will enable clinicians to overcome the practical limitations in the context of COVID-19 of the standard cardiac safety strategy that requires heavy patient interaction.”

Each patient in the study will receive a Withings Move ECG Watch linked to Cardiologs’ AI platform, which is already CE marked and FDA cleared for QT interval analysis and arrhythmia diagnostics. Throughout the 10-day course of treatment, daily ECG readings will be sent directly from the smartwatch to Cardiologs’ AI platform, where the data will be compared to the gold standard ECG measure and analyzed to assess drug-induced cardiotoxic risk as well as arrhythmic events.

“This study has implications for risk management of drug-induced cardiotoxicity, even beyond the current COVID-19 and hydroxychloroquine context,” said Professor Jag Singh, a cardiologist at Massachusetts General Hospital (MGH), Professor of Medicine at Harvard Medical School, and a scientific advisor to Cardiologs. “Personal ECG sensors could potentially find a role in the management of these patients, but also add value in other routine clinical care, since over 300 commonly used drugs may have similar QT-prolongation risks as hydroxychloroquine.”

Cardiologs is exploring the possibility of additional studies involving different wearable ECG monitors with partners in the United States.

About Cardiologs

Cardiologs is a medical technology company on a mission to democratize expert cardiac care through medical-grade artificial intelligence. Developed in partnership with leading institutions, the Cardiologs ECG Analysis Platform empowers clinicians worldwide to deliver cardiac diagnostics faster and more efficiently. CE-Marked and FDA cleared for arrhythmia diagnostics, device agnostic, the Cardiologs ECG Analysis Platform is built on a growing database of more than 3 million ECG recordings and is supported by a number of clinical publications.

Media Contact(s)
Andrea LePain
eMedia Junction
andrea@emediajunction.com
617-894-1153

Clinical Study Shows Cardiologs’ AI Reduces The False Positive Burden Of Implantable Loop Recorders By Almost 70%

15.07.2020

Data presented at HRS 2020 shows Cardiologs’ AI-system successfully eliminates more than two-thirds of atrial fibrillation false positives from ILR reports, alleviating the clinical burden associated with remote monitoring

PARIS and BOSTON, May 14, 2020 /PRNewswire/ — Cardiologs, a global leader in artificial intelligence (AI) for cardiac diagnostics, today in partnership with the Valley Health System revealed the results of a clinical study that found the Cardiologs’ AI-based ECG analysis solution reduces by almost 70% the false positives of atrial fibrillation (AF) detected by implantable loop recorders (ILRs).

“Remote monitoring of ILRs has become an integral part of the modern cardiology practice. However, the deluge of data and the challenges in distinguishing real events from false positives can be time consuming and can siphon resources and attention from more pressing needs,” said cardiac electrophysiologist Dr. Rod Passman, Director of the Center for Arrhythmia Research and Jules J. Reingold Professor of Medicine (Cardiology) and Preventative Medicine at Northwestern University Feinberg School of Medicine in Chicago.

To address the issue, Cardiologs partnered with the Valley Health System to test an AI-based solution on a cohort of 348 patients who received an ILR for either Atrial Fibrillation (AF) or Cryptogenic Stroke (CS). The ILR ECG strips with 1,190 detected AF episodes were then uploaded into Cardiologs’ cloud-based platform and filtered through Cardiologs’ AI-based algorithm. The results show Cardiologs reduced the number of false positive episodes by 69.7% and 62% in the CS and known AF cohorts respectively – with a 1.7% and 0.6% corresponding false negative rate. The findings were first presented at the Heart Rhythm Society in May 2020 and will be published in HeartRhythm later this month.

“The use of ILRs has been a great addition to the long-term heart monitoring tool set. But the large amount of data associated with extended monitoring and specifically the high level of false positive AF detections have created a considerable burden in the management of ILR data. The Cardiologs’ AI solution offers remarkable promise to alleviating the heavy clinical burden associated with managing ILR patients,” said cardiac electrophysiologist Dr. Suneet Mittal, Director of Electrophysiology, Associate Chief of Cardiology, Medical Director of the Snyder Atrial Fibrillation Center, Director of Cardiac Research at Valley Health System, and lead investigator of the study.

“We are excited about the continuously expanding use of the Cardiologs AI platform,” said Yann Fleureau, Cardiologs’ Co-Founder and CEO. “It’s reaffirming to receive even more clinical validation – demonstrating the tremendous value and benefits that come with using the solution. We look forward to working with ILR users around the world in the months to come.”

About Cardiologs

Cardiologs is a medical technology company committed to transforming cardiac diagnostics using medical-grade artificial intelligence and cloud technology. Developed in partnership with leading physicians, the Cardiologs ECG Analysis Solution empowers clinicians worldwide to deliver expert cardiac care faster and more efficiently. CE-Marked and FDA cleared for detection of 14 cardiac arrhythmias, the Cardiologs ECG Analysis Solution is built on a growing database of more than 4 million ECG recordings and is supported by a number of clinical publications.

Andrea LePain
eMedia Junction
andrea@mediajuntion.com
617-275-8112

Cardiologs Raises $15 Million in Series A Funding Led by Alven

10.01.2020

Funding will accelerate adoption of the company’s breakthrough AI-based heart disease diagnostic solution by supporting physicians with unprecedented EKG data analysis and reporting capabilities

PARIS and BOSTON, Jan. 10, 2020 /PRNewswire/ — Cardiologs, a global leader in artificial intelligence (AI) cardiology diagnostics, today announced that it has secured  $15 million in Series A funding, bringing the total capital raised since Cardiologs’ inception to more than $25 million. The financing round was led by Alven, a leading venture capital firm in Paris known for its impressive track record of investing in and expanding into the U.S. successful technology startups founded by French entrepreneurs.  Previous backers Bpifrance, ISAI, Kurma Diagnostics, Idinvest Partners and Paris Saclay Seed Fund also participated in the round.

“We have developed a new category of heart disease diagnostic products powered by AI that promise to revolutionize healthcare by delivering accurate, cost-effective and timely expert-level diagnostics,” said Yann Fleureau, co-founder and CEO of Cardiologs. “We are excited to work with our new partners at Alven and other earlier investors as we enter the next critical stage of our evolution as a company.”

Building off of strong revenues growth in 2019, notably in the U.S., Cardiologs intends to use the new funding to immediately grow its market share by ramping up sales and marketing efforts across North America and Europe. The money will also be used to further build the pioneering technology platform with new integrations and expanded applications.

“With its unique software built around a cutting-edge technology that blends deep learning with diagnostic clinical science and workflow, Cardiologs is already improving a traditionally manually-processed industry to generate substantial improvements in the speed, cost and accuracy of diagnostics.” says François Meteyer, Partner at Alven. “This will be a key differentiator to build a new AI-based category in the cardiology field, democratizing the access to instant, reliable and affordable expertise for every patient, every test, everywhere. We’re excited to support this European-rooted global business in its development .”

“We’ve been impressed by Cardiologs’ achievements since the seed round and we’re very excited to invest again and help build a category leader in the medical diagnostic industry,” commented Jonathan Userovici, Investment Manager at Idinvest Partners, an opinion shared by Jean-Patrice Anciaux, Investment Director at Bpifrance Digital Venture and also an early investor in the company.

Cardiologs’ ability to quickly detect and diagnose heart conditions as effectively as the world’s top human cardiologists has promising implications. The AI model, which was trained on more than 1.4 million ECG recordings, is capable of spotting more than 100 different cardiac abnormalities and is FDA- cleared for all clinically-relevant arrhythmias. In addition, the system can interpret data from a broad range of cardiac monitoring devices and generate a report within minutes, enabling faster and more efficient diagnosis for patients.

Founded in Europe in 2014, Cardiologs has grown into a global brand and is already assisting clinicians across four continents with identifying heart rhythm abnormalities. The company continues to grow due to strong demand for accurate, cost-effective and timely heart disease diagnostics in the global healthcare market.

About Cardiologs
Cardiologs is a medical technology company committed to transforming cardiac diagnostics using medical-grade artificial intelligence and cloud technology.  Developed in partnership with leading physicians, the Cardiologs ECG Analysis Solution empowers clinicians worldwide to deliver expert cardiac care faster and more efficiently.  CE-Marked and FDA cleared for detection of 14 cardiac arrhythmias, the Cardiologs ECG Analysis Solution is built on a growing database of more than 1.4 million ECG recordings and is supported by a number of clinical publications.

About Alven
Alven is an independent venture capital fund with over $500 million in assets under management and nearly 130 companies financed in 20 years. Alven’s mission is to support the long-term success of outstanding European digital & technology entrepreneurs.
Amongst the investments made by Alven are Algolia, Dataiku, Drivy (bought by Getaround), Happn, Captain Train (Trainline/KKR), Bime Analytics (Zendesk), Webhelp, Peopledoc, Sqreen, Meero, Qonto, or MeilleursAgents (recently bought by Axel Springer).
Find out more at www.alven.co

About Idinvest
Idinvest Partners is a leading European mid-market private equity firm. With €8bn under management, the firm has developed several areas of expertise including innovative startup venture capital transactions; mid-market private debt, i.e. senior and subordinated debt; primary and secondary investment and private equity advisory services. Founded in 1997, Idinvest Partners used to belong to the Allianz Group until 2010, when it branched out as an independent firm. In January 2018, Idinvest Partners became a subsidiary of Eurazeo, a leading global investment company, with a diversified portfolio of €17.7bn in assets under management, including nearly €11.6bn from investment partners, invested in nearly 400 companies.

About Bpifrance and Bpifrance Digital Ventures
Bpifrance is the French national investment bank: it finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services (training, consultancy.) to help entrepreneurs meet their challenges (innovation, export…).
Bpifrance Digital Venture is the VC team within Bpifrance, dedicated to digital and tech companies aiming to become global leader on their market. It focuses on Seed and Series A/B stages. With €650 million under management, the team backed nearly 80 companies and had 10 exits since 2011. Amongst the investments made by Bpifrance Digital Venture team are Teads (bought by Altice), Talentsoft, Netatmo (Legrand), Meilleurs Agents (Axel Springer), Balyo, Manomano, Evaneos, Openclassrooms, GitGuardian, Strapi, Numworks.

For more information, please visit: www.bpifrance.fr and presse.bpifrance.fr 
Follow us on Twitter: @Bpifrance – @BpifranceDV – @BpifrancePresse

About Kurma Partners
Kurma Partners is a key European player in the financing of innovation in healthcare and biotechnology, notably through Kurma Biofund I and II, Kurma Diagnostics and strategic partnerships with prestigious European research and medical institutions.
www.kurmapartners.com

About ISAI
Launched in 2010, ISAI is the Tech Entrepreneurs’ Fund and brings together a community of over 250 entrepreneurs around the world.
Nearly 200 successful entrepreneurs, who have invested in ISAI funds, and more than 50 ISAI-backed start-up co-founders share the collective ambition of co-writing great entrepreneurial stories. ISAI invests in differentiated projects run by ambitious teams that it selects rigorously and actively supports. ISAI Gestion, an investment management company approved by the AMF, with over €400 million under management, aims to finance and support high potential Tech companies, at the seed/post-seed stage (venture capital, ticket from €150k ticket to €2m with participations in successive rounds) or when they have already reached the break-even stage (Tech Growth/LBO, tickets from €5m to €30m).
More information on www.isai.fr/en

Media Contact 
Andrea LePain
andrea@emediajunction.com 
eMedia Junction
617-275-8112

SOURCE Cardiologs

Related Links

https://cardiologs.com/

Cardiologs CEO Named European Innovator of the Year

05.12.2018

Cardiologs Co-founder & CEO named to MIT Technology Review’s ‘Innovator under 35’ and BNP Paribas’ ‘European Innovator of the Year’.

A medtech company transforming cardiac diagnostics using medical-grade artificial intelligence (AI) and cloud technology, announced today that co-founder and CEO, Yann Fleureau, has been named one of MIT Technology Review’s Innovators Under 35 Europe 2018. He was honoured during an award ceremony in Paris on December 4, 2018. Additionally, Yann Fleureau has been selected among the 35 laureates as BNP Paribas European Innovator of the Year.

Selected from a pool of more than 1,000 candidates, the 35 innovators were awarded as part of a community of leaders that are changing the future of technology. Yann was specifically recognised for revolutionising cardiac care through his work developing a cloud-based AI platform that can quickly and accurately analyse electrocardiograms (ECGs).

“I’m deeply honoured to be selected to receive this prestigious award and am humbled to be included among the many talented innovators who are using technology to benefit humankind,” said Yann. “This technology not only improves cardiac diagnostic efficiency and analysis of ECGs, but also democratises access to make expert cardiac diagnostics more available in developing countries and emerging markets. I’m proud of the work our team has done. We’re excited to build on this recognition and continue to extend our solution’s reach and data collection to serve a greater community of doctors and patients.”

Cardiologs’ technology, which can be universally accessible from any device, supports doctors by helping identify patterns and predict irregularities the heart’s electrical activity  – empowering physicians to better diagnose and address patients’ heart conditions. It’s the first commercially available algorithm for analysing ECGs based on deep learning technology, and among only a few AI solutions to have received regulatory clearance for clinical use. The system is currently CE-Marked in Europe and has received FDA clearance to aid physicians in screening for arrhythmias such as atrial fibrillation using ambulatory ECG recordings. The solution is now in clinical use across four continents.

“With Cardiologs and their use of AI in cardiac diagnostics, Yann Fleureau proposes a technological revolution in a tool that has been used in clinical practice for many years, but whose potential is now growing exponentially with the availability of new devices capable of recording ECGs,” said Innovators Under 35 Europe’s organising team. “With Cardiologs, we now have a scaleable expert analysis solution that can help make sense of this new flow of valuable clinical information and can form a key building block in the medicine of the future”.

About Cardiologs

Cardiologs is a medical technology company committed to transforming cardiac diagnostics using medical-grade artificial intelligence and cloud technology.  Developed in partnership with leading physicians, the Cardiologs ECG Analysis Solution empowers clinicians worldwide to deliver expert cardiac care faster and more efficiently.  CE-Marked and FDA cleared for detection of 14 cardiac arrhythmias, the Cardiologs ECG Analysis Solution is built on a growing database of more than 600,000 ECG recordings and is supported by a number of clinical publications.